193 related articles for article (PubMed ID: 36774428)
21. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.
Perdrizet J; Santana CFS; Senna T; Alexandre RF; Sini de Almeida R; Spinardi J; Wasserman M
Hum Vaccin Immunother; 2021 Apr; 17(4):1162-1172. PubMed ID: 32966176
[TBL] [Abstract][Full Text] [Related]
22. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece.
Gourzoulidis G; Barmpouni M; Kossyvaki V; Vietri J; Tzanetakos C
Front Public Health; 2023; 11():1229524. PubMed ID: 37841729
[TBL] [Abstract][Full Text] [Related]
23. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
[TBL] [Abstract][Full Text] [Related]
24. Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium.
Wilson MR; McDade CL; Perdrizet JE; Mignon A; Farkouh RA; Wasserman MD
Infect Dis Ther; 2021 Sep; 10(3):1765-1778. PubMed ID: 34250576
[TBL] [Abstract][Full Text] [Related]
25. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
de Boer PT; van Werkhoven CH; van Hoek AJ; Knol MJ; Sanders EAM; Wallinga J; de Melker HE; Steens A
BMC Med; 2024 Feb; 22(1):69. PubMed ID: 38360645
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population.
Lytle D; Grajales Beltrán AG; Perdrizet J; Ait Yahia N; Cane A; Yarnoff B; Chapman R
Hum Vaccin Immunother; 2023 Aug; 19(2):2257426. PubMed ID: 37771288
[TBL] [Abstract][Full Text] [Related]
27. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom.
Wilson M; Lucas A; Mendes D; Vyse A; Mikudina B; Czudek C; Ellsbury GF; Perdrizet J
Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514984
[TBL] [Abstract][Full Text] [Related]
28. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
Rozenbaum MH; Huang L; Perdrizet J; Cane A; Arguedas A; Hayford K; Tort MJ; Chapman R; Dillon-Murphy D; Snow V; Chilson E; Farkouh RA
Vaccine; 2024 Jan; 42(3):573-582. PubMed ID: 38191278
[TBL] [Abstract][Full Text] [Related]
30. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
Clin Infect Dis; 2023 Feb; 76(3):e1062-e1070. PubMed ID: 35789262
[TBL] [Abstract][Full Text] [Related]
31. Historical Population-Level Impact of Infant 13-Valent Pneumococcal Conjugate Vaccine (PCV13) National Immunization Programs on Invasive Pneumococcal Disease in Australia, Canada, England and Wales, Israel, and the United States.
Perdrizet J; Horn EK; Hayford K; Grant L; Barry R; Huang L; McDade C; Wilson M
Infect Dis Ther; 2023 May; 12(5):1351-1364. PubMed ID: 37079175
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ
Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria.
Pugh SJ; Fletcher MA; Charos A; Imekraz L; Wasserman M; Farkouh R
Infect Dis Ther; 2019 Mar; 8(1):63-74. PubMed ID: 30539417
[TBL] [Abstract][Full Text] [Related]
35. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics.
Palmborg A; Skovdal M; Molden T; Åhman H; Chen L; Banefelt J
PLoS One; 2023; 18(6):e0287378. PubMed ID: 37363884
[TBL] [Abstract][Full Text] [Related]
36. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation.
Shafie AA; Ahmad N; Naidoo J; Foo CY; Wong C; Pugh S; Tan KK
Hum Vaccin Immunother; 2020 Jul; 16(7):1719-1727. PubMed ID: 31951782
[TBL] [Abstract][Full Text] [Related]
37. Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
Prasad N; Stoecker C; Xing W; Cho BH; Leidner AJ; Kobayashi M
Vaccine; 2023 May; 41(18):2914-2921. PubMed ID: 37012118
[TBL] [Abstract][Full Text] [Related]
38. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
39. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country.
Castañeda-Orjuela C; De la Hoz-Restrepo F
Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
